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Background: Duplications of the X-linked MECP2 gene are associated with moderate to severe intellectual
disability, epilepsy, and neuropsychiatric illness in males, while triplications are associated with a more severe
phenotype. Most carrier females show complete skewing of X-inactivation in peripheral blood and an apparent
susceptibility to specific personality traits or neuropsychiatric symptoms.
Methods: We describe the clinical phenotype of a pedigree segregating a duplication of MECP2 found on clinical
array comparative genomic hybridization. The position, size, and extent of the duplication were delineated in
peripheral blood samples from affected individuals using multiplex ligation-dependent probe amplification and
fluorescence in situ hybridization, as well as targeted high-resolution oligonucleotide microarray analysis and
long-range PCR. The molecular consequences of the rearrangement were studied in lymphoblast cell lines using
quantitative real-time PCR, reverse transcriptase PCR, and western blot analysis.
Results: We observed a partial MECP2 duplication in an adult male with epilepsy and mild neurocognitive impairment
who was able to function independently; this phenotype has not previously been reported among males harboring
gains in MECP2 copy number. The same duplication was inherited by this individual’s daughter who was also affected
with neurocognitive impairment and epilepsy and carried an additional copy-number variant. The duplicated segment
involved all four exons of MECP2, but excluded almost the entire 3' untranslated region (UTR), and the genomic
rearrangement resulted in a MECP2-TEX28 fusion gene mRNA transcript. Increased expression of MECP2 and the
resulting fusion gene were both confirmed; however, western blot analysis of lysates from lymphoblast cells
demonstrated increased MeCP2 protein without evidence of a stable fusion gene protein product.
Conclusion: The observations of a mildly affected adult male with a MECP2 duplication and paternal transmission of
this duplication are unique among reported cases with a duplication of MECP2. The clinical and molecular findings
imply a minimal critical region for the full neurocognitive expression of the MECP2 duplication syndrome, and suggest
a role for the 3′ UTR in mitigating the severity of the disease phenotype.
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The MECP2 gene maps to chromosome Xq28 and en-
codes a methyl CpG binding protein that acts as a tran-
scriptional repressor or activator for genes associated
with nerve cell function [1]. Duplications of MECP2 have
been described as the cause of Lubs syndrome (OMIM
#300260), an X-linked recessive disorder in which af-
fected males manifest a variety of moderate to severe
neurological and cognitive phenotypes, including hypo-
tonia, delayed or absent speech, intellectual disabilities,
epilepsy, late-onset spasticity, as well as feeding diffi-
culties and recurrent respiratory infections [2-7]. Most
males have a reduced life-span, with death occurring
within the first three decades of life; although older sur-
viving individuals with severe impairment have been
reported [8,9].
Most reported MECP2 duplications are inherited from
unaffected or mildly affected carrier mothers, with fewer
arising de novo; as yet there have been no reported in-
stances of paternal inheritance [4,10,11]. Carrier mothers
typically have normal intelligence and demonstrate near
100% inactivation of the duplication-bearing X chromo-
some in DNA isolated from peripheral blood, but on
more detailed testing most also have an apparent sus-
ceptibility to specific personality traits or neuropsychi-
atric concerns such as depression and anxiety [10,12].
Affected females with X:autosome translocations can
have a phenotype that is similar to that seen in affected
males; more typically, however, they have partially
skewed X chromosome inactivation patterns with milder
clinical features than affected males that include short
stature, intellectual disability, body asymmetry and epi-
lepsy [9,13-15].
Genotype-phenotype correlation studies suggest that
the minimal duplicated region required to recapitulate
the MECP2 duplication phenotype includes the entire
MECP2 coding sequence and the neighboring IRAK1
gene, and that MECP2 is the primary dosage-sensitive
gene mediating neurological outcomes [4,11,16,17]. This
contention is further supported by a highly penetrant
and more severe neurological phenotype observed with
triplications of MECP2 [12]. The molecular mechanisms
modulating MECP2 expression are complex and include
a variety of cis-acting regulatory units, micro-mRNAs,
and alternate transcripts [18]. The relative contributions
and molecular interactions of these regulatory motifs,
however, have yet to be fully elucidated, making the
functional regulation of MECP2 expression a subject of
intense study and interest.
Here we provide extensive molecular characterization
of a MECP2 duplication occurring in a mildly affected
adult male and subsequently transmitted to his affected
daughter. The uniquely small size of the duplication, to-
gether with the unusual molecular and clinical attributesof the affected family, provided the opportunity to po-
tentially gain functional insights into the neurocognitive
phenotype of MECP2 duplication syndrome.
Results
Neurocognitive abnormalities in a family segregating two
copy number variants (CNVs)
Consultand
The consultand was a Caucasian female who presented
at age three years and 10 months, after mild early delays
in fine and gross motor development, with loss of speech
and significant behavioral problems including attention
deficit hyperactivity disorder (ADHD) and aggression.
She also had hyperacusis, sensitivity to textures and poor
eye contact. Formal autism evaluation using the Gilliam
Autism Rating scales (GARS) was consistent with a diag-
nosis of pervasive developmental disorder not-otherwise-
specified (PDD-NOS), and she was noted to also have
problems with cognitive processing. She subsequently
developed focal onset seizures and was diagnosed with
epilepsy. She was proportionately large for her age
(height between 75th - 90th percentiles, weight and head
circumference at the 97th and 98th percentiles respect-
ively) with mild dysmorphic features (smooth philtrum,
double ear crus, over-folded helix, bilateral 5th finger
clinodactyly, talus rotation). When seen at age six years,
her seizures were medically refractory, and she had a
limited vocabulary with difficulties in speech articulation
and required help with dressing and undressing.
Father
The 34-year-old father of the consultand related pro-
blems with speech and cognition in childhood that
necessitated special education and speech therapy. He
completed twelve years of school, and recalled being re-
ferred to as learning disabled. He was unable to read or
to write. Specific developmental milestones were un-
available, but he did not recall a history of develop-
mental delay. He experienced enuresis until age 18 years
and epilepsy with generalized tonic-clonic seizures that
began in infancy and continued until pre-adolescence.
He did not endorse a history of childhood hypotonia,
spasticity, ambulation problems, hospitalization, or fre-
quent or recurrent infections. He was otherwise healthy
and on no regular medications. He described himself as
being moody and depressed, and he responded positively
to all questions on a standard Mood Disorder Question-
naire [19]. On exam, his head circumference was normal,
and he was non-dysmorphic apart from short palpebral
fissures (more than four standard deviations below nor-
mal). He had a normal gait. He was conversant and
friendly, but his cognitive processing appeared slow. He
described living an itinerant lifestyle with intermittent
employment as a day worker, and he gave no formal
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clined, and he has not been available for further medical
evaluation.
Pertinent family history
The remainder of the pedigree (Figure 1) was significant
for a 4-year-old brother of the consultand with somnam-
bulism and other sleep-related complex behaviors,
ADHD, and Autism Spectrum Disorder (ASD). The con-
sultand’s mother related difficulty maintaining employ-
ment as a result of problems with cognitive processing
and executive functioning, for which she received special
education during high school. The mother was otherwise
healthy. In addition, a maternal half brother was diag-
nosed with sleep problems and ADHD.
Partial duplications of MECP2
Microarray-based comparative genomic hybridization
(array CGH) on DNA isolated from peripheral blood
demonstrated two abnormalities in the consultand: a
gain on chromosome 4q35.2 encompassing the MTNR1A
and FAT1 genes, sized between 194 and 296 kb, which
was also present in the mother and both affected male
siblings; and a gain on chromosome Xq28 estimated at
approximately 115 kb involving the MECP2 gene
(Additional file 1). Array CGH of both parents and the
consultand’s male half- and full- siblings indicated that
the Xq28 gain in the consultand was paternally inherited
and not present in either of the siblings (Figure 1).
Fluorescence in situ hybridization (FISH) studies con-
firmed an interstitial duplication of Xq28, and multiplex
ligation-dependent probe amplification (MLPA) con-
firmed that all four exons of MECP2 were duplicated in
both the consultand and her father (Additional file 2).
X-inactivation studies (XCI) performed using the con-
sultand’s DNA showed a moderately skewed pattern
(83/17) in peripheral blood cells, with preferential in-
activation of the paternally-inherited X-chromosome.
Further analysis using a high-resolution oligonucleotide
microarray spanning the MECP2 locus narrowed down
the breakpoint junctions to a downstream breakpointFigure 1 Pedigree of affected family. The pedigree shows segregation o
the family.just distal (3′) of the gene and an upstream breakpoint
more than 100 kb proximal (5′) of the gene (Figure 2a).
A specific breakpoint junction product was obtained by
PCR of DNA extracted from peripheral blood and con-
firmed in DNA from transformed lymphoblast cell lines in
those samples that carried the duplication (i.e. consultand
and father) (Figure 2b). Sanger dideoxy sequencing of the
PCR product revealed no microhomology at the junction,
suggesting Non-Homologous End Joining (NHEJ) as the
mechanism for formation [11]. The proximal (centro-
meric) breakpoint mapped within exon 4 of MECP2, spar-
ing almost the entire 3' UTR including three of the four
postulated alternative polyadenylation sites [20]. The distal
(telomeric) breakpoint mapped to an intron in one of two
identical upstream pseudogenes of TEX28, implying that
the full size of the duplication was 184.6 or 222.4 kb.
Genomic context of the MECP2 rearrangement
We investigated whether the juxtaposition of the dupli-
cated MECP2 gene adjacent to TEX28 (Figure 3a) pro-
duced a fusion gene that might be relevant to the
familial phenotypes. PCR was performed using cDNA,
with primers designed at the ends of exon three of
TEX28 and exon four of MECP2. We identified a gen-
omic rearrangement-associated novel fusion gene in the
father and consultand daughter exclusively, using RNA
extracted from lymphoblast cell lines. This result was
consistent with partial expression of the MECP2 dupli-
cated product in the peripheral blood of the consultand,
despite her having moderately skewed X-inactivation.
Sequencing of the resulting PCR product (Figure 3b)
confirmed the gene fusion.
We next sought to determine whether the insertion of
a partial copy of MECP2 in a new genomic context
would still be associated with increased MECP2 tran-
scription. We used the transcriptional expression of the
MECP2A isoform (also known as MECP2-e2 isoform) as
a surrogate marker of the normal MECP2 copy, as this
isoform is known to be expressed in lymphoblasts [21].
We found that relative to control lymphoblast cell lines,
the father demonstrated markedly increased MECP2Af two copy number variants (CNVs) and neurocognitive diagnoses in
Figure 2 Molecular characterization of the duplication involving MECP2. a. High-resolution oligonucleotide array CGH results for the
consultand (BAB3149) and father (BAB3150) showing a partial duplication of MECP2; b. PCR assay and sequencing result for the breakpoint
junction of the duplication flanked by primers 3149R1+ FE. The junctional fragment was observed exclusively in those wells corresponding to
consultand (BAB3149) and father (BAB3150); c. Smallest region of overlap (SRO) surmised from a cohort of 30 patients with MECP2 duplication
syndrome [11] encompassing HCFC1, IRAK1, MECP2 as well as all known MECP2 cis-regulatory regions (shown in green) [24], compared with the
partial duplication observed in the family (illustrated by BAB3150), which does not include the entire pre-defined SRO.
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typically observed in patients carrying MECP2 duplica-
tion and triplication (Figure 3c). This was not observed
for any other family members including the consultand.
The latter observation may reflect the fact that the
clonally obtained lymphoblast cell lines of the female
consultand demonstrated more extensive skewing of X-
inactivation (96/4, versus 83/17 in peripheral blood) as a
consequence of the cloning passage [22]; the lack of ap-
preciable increase in expression in the consultand is
therefore considered to be equivocal.
Having observed an apparent increase in MECP2A
transcription in the consultand’s father, we then sought
to determine whether the increased MECP2 transcrip-
tion would result in an increase in MeCP2 protein or
MeCP2-TEX28 fusion protein. Proteins were extracted
from immortalized lymphoblast cell lines of all available
family members and a male and female control cell line.MeCP2 protein levels were then quantified and compared
to total histone H3 levels used as loading control. Con-
sistent with the results from the transcription experi-
ment, lymphoblasts of the consultand’s father (BA3150)
produced 1.9-fold the amount of MeCP2 protein than cells
from control individuals, while the other family members
(including the consultand (BA3149)) had MeCP2 protein
levels similar to normal control individuals (Figure 4).
Further, there was no evidence of an additional band in
the consultand or her father, which would be expected if
a viable fusion protein (MeCP2-TEX28) were formed.
Discussion
A MECP2 duplication, partial or complete, occurring in
an adult male with minimal symptomatology has not, to
the best of our knowledge, been previously reported; nei-
ther has paternal transmission of a MECP2 duplication
to an affected female offspring. This family is thus both
Figure 3 Structural depiction and functional assay of partial MECP2 duplication. a. Genomic structure for consultand (BAB3149) and father
(BAB3150) surmised using array CGH and breakpoint sequencing analysis. Both wild type (reference) and post-duplication structures are shown
for comparison; b. PCR assay and sequencing results for the MECP2-TEX28 fusion gene junction flanked by primers Exon4_R + TEXon2_F3; c.
Relative MECP2A mRNA assay for affected family (HOU1230). Control samples: CTL02 and 3059 are males carrying one copy of MECP2; CTL01 is a
female carrying one copy of MECP2; 2623 and 2666 are male patients carrying two copies of MECP2 [11]; 2805 is a male patient carrying three
copies of MECP2 [12]. Relative fold of mRNA expression changes were calculated using the comparative threshold cycle method (ddCT).
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duplications. In the affected male, the partial duplication
is associated with increased MECP2 expression and
MeCP2 protein production, and occurs in the context of
a clinical presentation that is distinct from the ‘typical’
phenotype of adult males with MECP2 duplication, who
usually manifest a greater degree of neurological impair-
ment. The key to this apparent phenotypic conundrum
appears to lie with the breakpoints, size, and ultimate
physical position of the duplicated segment, all of which
are also unique among reported MECP2 duplications.
We previously reported a series of 30 male patients
with MECP2 duplications [11], in which the duplication
sizes were between 250 kb and 2.6 MB - larger than the
184 or 222 kb size estimated for the consultand’s father.
A duplication of similar small size has been reported in
an apparently non-dysmorphic female referred for intel-
lectual disability [13], but this duplication was translo-
cated to chromosome 10, and no functional information
was reported. The reported smallest region of overlap
(SRO) in our series was approximately 140 kb andincluded both MECP2 and the neighboring IRAK1 gene
[4,11]. By comparison, in our present case, the genomic
breakpoints are more telomeric (Figure 2c), ostensibly
leaving IRAK1 dosage unperturbed. Increased IRAK1
gene dosage has been associated with a history of recur-
rent infections in some MECP2 duplication patients.
This assertion would be consistent with the father’s
negative history of recurrent respiratory or other infec-
tion; however, given the variable expressivity of the in-
fection phenotype, additional studies are needed to
determine whether increased IRAK1 dosage is necessary
and/or sufficient to manifest recurrent infections in
MECP2 duplication patients.
We speculate that the father’s neurological history, or
lack thereof - an affected male with speech delay and
epilepsy but without the hypotonia, spasticity, or degree
of cognitive and language impairment typically observed
in boys with MECP2 duplications – may be the conse-
quence of the specific rearrangement breakpoints within
the MECP2 gene. We detected increased expression of
the MECP2A mRNA isoforms in his blood and
Figure 4 Comparison of MeCP2 protein levels in pedigree
members. MeCP2 protein levels are normalized to histone H3.
Individuals 3149 (consultand), 3169 (mother), 3170 (maternal half-
brother) and 3171 (brother) have MeCP2 protein levels similar to
normal control individuals (female control – CTL01, male control –
CTL02); lymphoblasts of individual 3150 (father) produced 1.9-fold
the amount of MeCP2 protein observed in cells from control individuals.
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There is evidence from the literature that the MECP2A
isoform may not be as biologically relevant in brain as
isoform MECP2B [21]. In fact, the ‘long’ MECP2 tran-
script of 10.2 kb, which is the predominant transcript in
the brain, appears to correspond to MECP2B and is
present in full only once in this present rearrangement.
The duplicated region is predicted to produce only the
‘short’ MECP2 transcript of 1.8 kb, which has higher ex-
pression in non-neurological tissues such as heart and
muscle [21]. Recent studies using a Cre-LoxP system
that specifically disrupts the MECP2A isoform (also
known as MECP2-e2) have demonstrated that specific
loss of the short transcript does not result in a neuro-
logical phenotype in mice [23]. Alternatively (or in
addition), it is possible that in the absence of MECP2-
associated cis-regulatory elements [24] from the dupli-
cated segment (Figure 2c), the regulation of the dupli-
cated copy in brain may be different from that observed
with the wild-type copy. These observations concur with
mouse models of Rett syndrome in which disruption of
the 3'UTR has been shown to alter MeCP2 protein sta-
bility and activity [25,26]. The genomic configuration of
the rearrangement together with the clinical picture, lead
us to speculate that the overall dosage effect of MECP2
on neuronal activity may be mitigated by effects attribut-
able to the unduplicated 3' UTR segment, resulting in
fewer adverse clinical manifestations than are typically
seen.Lastly, although both the consultand and her father
share the same duplicated segment, the consultand
clearly had a more severe phenotype than her father. It
is unusual to find a female with a duplication of MECP2
who is more severely affected than a male family mem-
ber, since, by definition; females cannot have more skew-
ing than males. Although there exists the possibility of
rare cis-acting modifiers of transcription and/or transla-
tion a more parsimonious explanation is of a ‘2nd hit’ in
which an additional genomic event (structural variant or
point mutation) results in a more severe phenotype in
the consultand than that expected from the father’s
MECP2 duplication [27-29]. The segregation of other
neurocognitive phenotypes within the nuclear family
gives further credence to this suggestion; the consul-
tand’s mother and two maternal siblings demonstrated a
range of neurocognitive and behavioral phenotypes that
were similar to the consultand, but none gave a history
of seizures. It may be that seizures and some of the neu-
rocognitive defects segregate with the partial MECP2
duplication, whilst autistic features, other additional cog-
nitive defects, and sleep problems are the result of a 2nd
hit. As the immediate maternal family members all carried
the 4q35 duplication, but not the MECP2 duplication, the
4q35 duplication could represent the 2nd genomic hit in
this family. The 4q35 CNV is a small 100 kb region that
encodes the melatonin receptor MTNR1A and the tran-
scription factor FAT1. Neither of these genes are known
to be dosage-sensitive or disease-causing and a prelimin-
ary enquiry of the DECIPHER database (The DECIPHER
Consortium, http://decipher.sanger.ac.uk) indicates that
larger encompassing duplications have been seen, with-
out a clear clinical phenotype and occasionally inherited
from a reportedly normal parent. The segregation of the
phenotypes in this family, however, suggests that there
may yet be a role for this region in neurocognition and
sleep. This is a subject of ongoing study in our laboratory.
Conclusion
Our findings lead us to suggest that the severe neuro-
logical and cognitive phenotypes typically observed in
the MECP2 duplication syndrome result from duplica-
tion of the entire MECP2 coding and cis-regulatory ele-
ments. This is consistent with the observation that most,
if not all, of the neurological phenotypes observed in the
MECP2 duplication syndrome can be recapitulated by
duplication of MECP2 alone in mice [16]. Tacitly, our
findings imply that copy number gain of the ‘short’, as
opposed to the ‘long’, MECP2 transcript and/or disrup-
tion of specific 3' regulatory motifs may be associated
with an overall milder neurocognitive phenotype, but
one that remains susceptible to the development of
epilepsy. Given that interpretation of the likely clinical
consequences of intragenic duplications can often be
Hanchard et al. BMC Medical Genetics 2012, 13:71 Page 7 of 9
http://www.biomedcentral.com/1471-2350/13/71challenging without specific breakpoint resolution of
the rearrangement [30,31], our findings have potential
prognostic implications for genetic counseling of males
with intragenic duplications of MECP2. Further studies
of the role of the 3′ UTR in modifying the MECP2
duplication phenotype are required to validate the hy-
potheses generated from this unique family, but, if
confirmed, this could become an avenue of fertile and
important research going forward.
Methods
Samples
Initial samples from the consultand daughter (BAB3149)
were received as a part of her clinical diagnostic eval-
uation; thereafter, written informed consent was pro-
cured for additional research testing on samples from
the consultand (BAB3149) as well as the remainder of the
nuclear family members (BAB3150 - father, BAB3169 -
mother, BAB3170 - maternal-half brother, BAB3171-
brother). All studies were performed with the approval of




obtained with trypsin and Giemsa) chromosome ana-
lysis, FISH, and MLPA analyses were performed at Bay-
lor College of Medicine Medical Genetics Laboratories
(http://www.bcm.edu/geneticlabs/) as described previ-
ously [4,32]. X-inactivation studies were based on the
protocol described by Allen [32,33] with modifications
as described previously [10].
Duplication size and genome content
To determine the size, genomic extent and gene con-
tent for each rearrangement, we designed a tiling-
path oligonucleotide microarray spanning 4.6 Mb
across the MECP2 region on Xq28. The custom
4x44k Agilent Technologies (Santa Clara, CA) micro-
array was designed using the Agilent e-array website
(http://earray.chem.agilent.com/earray/). We selected
22,000 probes covering ChrX: 150,000,000-154,600,000
(NCBI build 36), including the MECP2 gene, which
represents an average distribution of 1 probe per
250 bp. Probe labeling and hybridization were per-
formed as described previously [11].
Quantitative real-time PCR
Total RNA was extracted from immortalized lympho-
blast cell lines from all family members, three controls
without copy number variation in the Xq28 region
(CTL01, female control; CTL02, male control; 3059 male
control), two individuals carrying MECP2 duplications
(BAB2623 and BAB2666)[11], and one individual carryinga MECP2 triplication (BAB2805)[12]. RNA extraction
was carried out on lymphoblasts using TRIzol reagent
(Invitrogen Corporation, Carlsbad, CA); this was
DNaseI treated and purified using the RNeasy mini
kit according to the manufacturer’s protocol (Qiagen,
Valencia, CA). cDNA was synthesized from 1 μg of
RNA using qScript cDNA Super Mix (Quanta Bios-
ciences, Gaithersburg, MD). Quantitative real-time
PCR reactions were performed using TaqMan expres-
sion assay Hs00172845_m1 from Applied Biosystems
(ABI; Life Technologies, Carlsbad, CA) that specifically
detects MECP2A transcript. Experiments were carried
out according to the manufacturer’s protocol. Four
technical replicates were performed for each genomic
DNA sample and normalized relative to TBP levels.
Reactions were run on the ABI 7900HT fast system.
Relative fold of mRNA expression changes were calcu-
lated using the comparative threshold cycle method
(ddCT).PCR amplifications
Primers for long-range PCR were designed at the ap-
parent boundaries, as denoted by transitions signifying
a gain of the duplicated segment relative to the refer-
ence genome as inferred from the custom oligonucleo-
tide microarray result. Long-range PCR was performed
using TaKaRa LA Taq (Clontech, Mountain View, CA).
Primers to obtain the breakpoint junction 3149R1:
5'AGAGAAGATGGATATGACCAGTGGC 3′ and’ FE: 5'
GCCTCACCTACACTTCTCCTCCTG3'. Primer 3149FW1:
5′ TCTACATGTGTGCCTCACT 3′ was used to walk
across the 3149R1+ 3149FE PCR product. Detection of the
transcript from the fusion gene junction was performed
using cDNA from primers: Exon4_R:CCGTGACCGA
GAGAGTTAGC and TEXon2_F3:ACTGGCCTTCTCCA
CTCTCA.Acid extraction of protein and western blot analysis
Proteins were isolated via acid extraction from confluent
cultures of immortalized human lymphoblast cell lines
of subjects BA3149, BA3150, BA3169, BA3170, BA3171,
a male control individual, and a female control individ-
ual. Acid extraction of protein, western blotting, and
Immunodetection with anti-MeCP2 antibody 0535, were
performed according to our previously published proto-
col [10]. Immunodetection with antihistone H3 antibody
(Millipore, Billerica, MA, #06-755, 1:100,000 dilution)
was performed as a loading control. MeCP2 and histone
H3 protein levels were quantified using ImageJ software
(National Institutes of Health, Bethesda, MD) and the
total MeCP2 protein level was normalized to the level of
histone H3 protein detected for each subject.
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Additional file 1: Clinical arrayCGH of MECP2 and adjacent regions
in consultand. Description: The array plot illustrates a gain in copy
number (green dots) spanning MECP2 and the adjacent 5′ region in the
consultant (BAB3149). Black dots represent normal gene dosage
(hybridization intensity) compared to sex-matched controls. Red dots
represent oligos with log2 ratios less than −0.3 suggestive of a
heterozygous loss.
Additional file 2: Clinical laboratory confirmation of MECP2
duplication. Description: a. MLPA of MECP2 in the consultand’s father
(BAB3150) demonstrating increased dosage (blue peaks) compared with
a normal male control (red peaks). Red asterisks indicate the duplicated
MECP2 exons, with MECP2_exon 01 (Start) and MECP2_exon04c (End)
probes representing the first and the last duplicated probes in the
coding region. Probes located in the proximal L1CAM gene and in the 3′
UTR of the MECP2 gene (MECP2 exon 04b) show normal dosage. b.
Fluorescent in-situ Hybridization (FISH) using probes specific for the
duplicated region and showing the duplication to be on the X
chromosome.
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